Form 4: Akoya Biosciences CEO Brian McKelligon Reports Stock Transaction
SEC Form 4 Filing
Brian McKelligon, CEO of Akoya Biosciences, reports disposition of shares to cover taxes on a previously granted restricted stock unit award.
Summary
- On March 23, 2025, Brian McKelligon, the President and CEO of Akoya Biosciences, Inc. (AKYA), disposed of 7,550 shares of common stock to cover taxes related to a restricted stock unit (RSU) award.
- The shares were disposed of at a price of $1.7.
- Following the transaction, McKelligon directly owns 420,126 shares of Akoya Biosciences common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing a routine stock transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This transaction reflects the standard practice of covering tax obligations associated with equity compensation.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a routine sale of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/23/2022 | Date of original restricted stock unit award grant |
| 03/23/2023 | First vesting date of the restricted stock unit award |
| 03/23/2025 | Date of stock transaction (disposal of shares to cover taxes) |
| 03/25/2025 | Date of Form 4 filing |
Keywords
Akoya Biosciences, Brian McKelligon, Form 4, Stock Transaction, Restricted Stock Unit, AKYA, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.